The alternative text for this image may have been generated using AI. IgG is the predominant antibody isotype found in the female genital tract and serves as an important defence mechanism against ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab ...

The neonatal Fc receptor for IgG (FcRn) is responsible for the transfer of passive humoral immunity from the mother to the newborn in rodents and humans. Throughout life, FcRn contributes to effective ...

The unveiling of Johnson & Johnson’s full data from the phase 2 trial of nipocalimab in Sjögren's disease (SjD) suggest that both the Big Pharma and its competitor argenx are on the right track by ...

Immunovant has confirmed that its first-generation FcRn inhibitor has been scrapped, a month after the asset flunked a pair of phase 3 eye disease trials. The company first set out plans back in 2022 ...

The ongoing EPIC clinical trial is the first randomized head-to-head comparison of two neonatal Fc receptor (FcRn)-targeting treatments for generalized myasthenia gravis (gMG) in adults. The phase ...

Ray Lambert looks at the potential of humanized FcRn mice for evaluating the pharmacokinetics of mAbs. Due to their extraordinary specificity and pharmacokinetic (PK) behavior, human immunoglobulin ...

Please provide your email address to receive an email when new articles are posted on . FcRn receptors have received FDA approvals in generalized myasthenia gravis. Studies of FcRn receptors in RA and ...

Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering ...